Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)
NCT ID: NCT02945527
Last Updated: 2025-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2/PHASE3
4 participants
INTERVENTIONAL
2015-12-04
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
NCT00441285
Treatment of Patients With Active Neurocysticercosis in Eastern Africa
NCT03834337
Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis
NCT00001912
Epi Cystic Hydatid Disease Peru
NCT00138346
Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)
NCT02947581
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acetazolamide
750 mg acetazolamide p.o. divided in three dily doses, for 10 days
Acetazolamide
As described above
Dexamethasone
8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
Dexamethasone
As described above
No additional anti-edema treatment
No additional treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acetazolamide
As described above
Dexamethasone
As described above
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Perilesional edema on CT or MRI
* Normal lab values
Exclusion Criteria
* Status epilepticus
* Symptomatic intracranial hypertension
* Tuberculosis
* More than 7 days after seizure
* Pregnancy
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Peruana Cayetano Heredia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hector H. Garcia, MD, PhD
Role: STUDY_CHAIR
Universidad Peruana Cayetano Heredia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas
Lima, , Peru
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
62352
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.